TEVA-CHLORPROMAZINE TABLET

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

CHLORPROMAZINE (CHLORPROMAZINE HYDROCHLORIDE)

Disponible desde:

TEVA CANADA LIMITED

Código ATC:

N05AA01

Designación común internacional (DCI):

CHLORPROMAZINE

Dosis:

25.0MG

formulario farmacéutico:

TABLET

Composición:

CHLORPROMAZINE (CHLORPROMAZINE HYDROCHLORIDE) 25.0MG

Vía de administración:

ORAL

Unidades en paquete:

100/500/1000

tipo de receta:

Prescription

Área terapéutica:

PHENOTHIAZINES

Resumen del producto:

Active ingredient group (AIG) number: 0106167006; AHFS:

Estado de Autorización:

APPROVED

Fecha de autorización:

2011-03-08

Ficha técnica

_TEVA-CHLORPROMAZINE _
_ _
_Product Monograph _
_Page 1 of 18_
PRODUCT MONOGRAPH
PR
TEVA-CHLORPROMAZINE
Chlorpromazine Hydrochloride Tablets
25 mg, 50 mg and 100 mg
Teva Standard
Antipsychotic–Antiemetic
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
Canada, M1B 2K9
www.tevacanada.com
Date of Preparation:
December 11, 2012
SUBMISSION CONTROL NO: 154593
_TEVA-CHLORPROMAZINE _
_ _
_Product Monograph _
_Page 2 of 18_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................7
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
..............................................................................10
OVERDOSAGE
................................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
............................................................11
STORAGE AND STABILITY
..........................................................................................12
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................12
PART II: SCIENTIFIC INFORMATION
...............................................................................13
PHARMACEUTICAL INFORMATION
..........................................................................13
REFERENCES
..............................................................